| 辛伐他汀对腹型肥胖患者NAFLD发病率的影响及其机制 |
| |
| 引用本文： | 詹海勇,黄聪武.辛伐他汀对腹型肥胖患者NAFLD发病率的影响及其机制[J].中国医药指南,2011,9(18):182-183. |
| |
| 作者姓名： | 詹海勇 黄聪武 |
| |
| 作者单位： | 汕头大学医学院第二附属医院消化内科,广东,汕头,515041 |
| |
| 摘 要： | 目的探讨辛伐他汀对腹型肥胖患者NAFLD发病率的影响及其机制。方法收集86例腹型肥胖合并血浆高敏-C反应蛋白(Hs-CRP)升高患者,随机分为对照组(安慰剂10mg/qn,口服)和治疗组(辛伐他汀10mg/qn,口服),每3个月随访一次,评估两组患者NAFLD发病率、血浆ALT、AST、GGT、Hs-CRP、TG和TC水平,共随访1年;同时分析血浆Hs-CRP水平与NAFLD发病率间的关系。结果随访1年后,与对照组相比,治疗组患者NAFLD发病率较低(16.3%vs 32.6%,P<0.05),且血浆Hs-CRP水平也较低(2.3±0.4mmol/L vs 3.7±0.6mmol/L,P<0.05);Pearson相关分析结果提示NAFLD发病率与血浆Hs-CRP水平呈正相关(r=0.877,P<0.05)。结论辛伐他汀能够降低腹型肥胖患者NAFLD的发病率,其机制可能与辛伐他汀下调血浆Hs-CRP水平有关。
|
| 关 键 词： | 辛伐他汀 腹型肥胖 非酒精性脂肪性肝病 |
Effect and Mechanism of Simvastatin on the Incidence of NAFLD in Patients with Abdominal Obesity |
| |
| ZHAN Hai-yong,HUANG Cong-wu.Effect and Mechanism of Simvastatin on the Incidence of NAFLD in Patients with Abdominal Obesity[J].Guide of China Medicine,2011,9(18):182-183. |
| |
| Authors: | ZHAN Hai-yong HUANG Cong-wu |
| |
| Institution: | ZHAN Hai-yong,HUANG Cong-wu (Department of Gastroenterology,Second Affiliated Hospital of Shantou Medical University,Shantou 515041,China) |
| |
| Abstract: | Objective To investigate the effect and mechanism of simvastatin on the incidence of non-alcoholic fatty liver disease(NAFLD) in patients with abdominal obesity.Method Eighty-six abdominal obesity patients with serum high sensitivity C-reactive protein(Hs-CRP) elevation were enrolled and were randomly assigned into control group(placebo10mg/qn,p.o.) and therapeutic group(simvastatin 10mg/qn,p.o.).The incidence of NAFLD and the serum levels of ALT,AST,GGT,Hs-CRP,TG and TC were detected trimonthly and totally... |
| |
| Keywords: | Abdominal obesity Simvastatin Non-alcoholic fatty liver disease |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
